medigraphic.com
ISSN 1405-8790 (Print)

2022, Number 1-4

<< Back Next >>

Rev Mex Med Fis Rehab 2022; 34 (1-4)

Physiotherapy management of a patient with spinal muscular atrophy type 1 undergoing pharmacological treatment. Case report

Del VMA, Ramírez LCG, Mendoza SA, Galván GM

Language: Spanish
References: 7
Page: 27-34
PDF size: 333.83 Kb.


ABSTRACT

Spinal muscular atrophy (SMA) is an autosomal recessive disease, caused by degeneration of the motor neurons of the spinal cord anterior horn, which causes weakness and progressive muscular atrophy of proximal predominance and with a wide spectrum of severity. Currently there is a drug that is used to treat SMA, Nusinersen is the active ingredient of the drug, registered trademark with trade name Spinraza®, is a synthetic antisense oligonucleotide that results in a complete functional SMN protein, where it is expected that in conjunction with physiotherapy the clinical evolution will be modified; with better functional prognosis in this pathology. This study describes the physiotherapeutic management and clinical evolution of a 3-year-old and 6-month-old patient with a diagnosis of SMA treated with Spinraza® and physiotherapy at the Teletón Aguascalientes Children's Rehabilitation and Inclusion Center.


REFERENCES

  1. Ministerio de Sanidad, Servicios Sociales e Igualdad. Informe de Posicionamiento Terapéutico de nusinersen (Spinraza®) en atrofia muscular espinal. Agencia española de medicamentos y productos sanitarios. 2018, pp. 1-8.

  2. Alfaro LER, Acosta GH. Nusinersén en el tratamiento de la atrofia muscular espinal. Eficacia y seguridad. Sevilla: Agencia de Evaluación de Tecnologías Sanitarias de Andalucía (AETSA). 2017, pp. 1-25.

  3. Ministerio de Salud. Gobierno de Chile: Guía de práctica clínica cuidados respiratorios en personas con Atrofia muscular espinal. Subsecretaría de Salud Pública División de Prevención y Control de Enfermedades. 2015, pp. 1-55.

  4. Tizzano EF. La atrofia muscular espinal en el nuevo escenario terapéutico. Revista Médica Clínica Las Condes. 2018; 29 (5): 512-520.

  5. Castiglioni C, Levicán J, Rodillo E, Garmendia MA, Díaz A, Pizarro L et al. Atrofia muscular espinal: caracterización clínica, electrofisiológica y molecular de 26 pacientes. Rev Méd Chile. 2011; 139 (2): 197-204.

  6. Glanzman AM, Mazzone E, Main M, Pelliccioni M, Wood J, Swoboda KJ et al. Prueba infantil de trastornos neuromusculares (Chop Intend) del Children's Hospital of Philadelphia: desarrollo y confiabilidad de la prueba. Neuromuscular Disord. 2010; 20 (3): 155-161.

  7. Jiménez GMT. Fisioterapia en amiotrofia espinal infantil, a propósito de un caso clínico. Efisioterapia 2012. Disponible en: https://www.efisioterapia.net/articulos/fisioterapia-amiotrofia-espinal-infantil




2020     |     www.medigraphic.com